Literature DB >> 27872772

An Uncommon Feature of Chronic Granulomatous Disease in a Neonate.

Razieh Afrough1, Sayyed Shahabeddin Mohseni2, Setareh Sagheb1.   

Abstract

Chronic Granulomatous Disease (CGD) represents recurrent life-threatening bacterial and fungal infections and granuloma formation with a high mortality rate. CGD's sign and symptoms usually appear in infancy and children before the age of five; therefore, its presentation in neonatal period with some uncommon features may be easily overlooked. Here we describe a case of CGD in a 24-day-old boy, presenting with a diffuse purulent vesiculopustular rash and multiple osteomyelitis.

Entities:  

Year:  2016        PMID: 27872772      PMCID: PMC5107835          DOI: 10.1155/2016/5943783

Source DB:  PubMed          Journal:  Case Rep Infect Dis


1. Introduction

Chronic Granulomatous Disease (CGD) is a rare inherited disease of phagocytic system that leads to recurrent and severe bacterial and fungal infections with a high mortality rate [1, 2]. CGD is characterized by granuloma and abscess formation in the skin, liver, lungs, spleen, and lymph nodes. These granuloma and abscess are caused by the inability of macrophages to kill ingested organisms [2, 3]. Infants with CGD encounter life-threatening infections, so prompt diagnosis and treatment with broad spectrum antibiotics are crucial [4, 5]. CGD's sign and symptoms usually appear in infancy and children before the age of five [3]; therefore, its presentation in neonatal period with some uncommon features may be easily overlooked. We report a 24-day-old boy with an uncommon presentation of CGD.

2. Case Presentation

A 24-day-old boy was referred to our hospital with vesiculopustular rash in the periorbita, genitalia, foot, and sacroiliac regions. The patient was born to a 26-year-old primigravida woman after a full term gestation without any complications during pregnancy. His father and mother were cousins. His birth weight was 2700 gr. He was admitted to NICU due to respiratory distress and was discharged after 4 days with a healthy condition. Ten days after his birth, he developed a vesiculopustular rash progressively in periorbita, genitalia, foot, and sacroiliac regions. Fourteen days later, he was referred to our hospital and was admitted for further evaluation and treatment. There was no complaint of poor feeding or fever. In physical examination, his weight was 2950 gr. He was not ill or toxic. Neonatal reflexes were normal. Asymmetric vesiculopustular lesions partially ruptured with erosions and crusted ulcers were seen. They were found in the left periorbital region, scrotum, penis, and sacroiliac region and on the medial malleolus of the left ankle, with some necrosis having extension into the dorsal surface of the foot (Figure 1).
Figure 1

Vesiculopustular lesions ((a)–(d)).

We also found conjunctivitis with purulent discharge and dactylitis in the left foot. Examinations of other organs were normal (Figure 2).
Figure 2

Dactylitis in the left foot.

Routine laboratory tests, smear, and culture from lesions and lumbar puncture were performed (Tables 1 and 2). Chest X-ray was normal at the time of admission, so lung CT scan was not performed.
Table 1

Results of the routine laboratory tests.

Parameter Before treatmentAfter treatmentUnits
WBC15.211.3K/μL
 Neut5541%
 Lymph31.632.8%
 Mono11.921.9%
 Eos1.64%
RBC4.233.75M/μL
Hgb13.311.5g/dL
Platelet112582K/μL
CRP56.222mg/L
Table 2

Results of the lumbar puncture.

ParameterValue
Protein45 mg/dL
Glucose57 mg/dL
WBC1/μL
RBC700/μL
SmearNegative
CultureNegative
PCR for HSVNegative
Gram positive cocci were seen in direct smear from skin lesions, and culture was also positive for Staphylococcus aureus. Tzanck smear was negative for the Herpes Simplex Virus (HSV). Samples were sent to determine the specific mutation, but the results are not available yet. We started our treatment with a combination of broad spectrum antibiotics (meropenem and vancomycin) and local treatment with saline irrigation and sterile dressing and then modified it to vancomycin and amikacin when culture results were available. According to the severity and extension of the lesions, a consult with a dermatologist and an immunologist was requested. Skin biopsy showed necrotizing granulomatous tissue reaction, with infectious etiology. Nitroblue tetrazolium (NBT) and Dihydrorhodamine (DHR) tests were performed for confirming diagnosis. Osteomyelitis of the left ankle, right elbow, and right wrist was seen in Tc99m whole body scan (Figure 3).
Figure 3

Osteomyelitis of the left ankle, right elbow, and right wrist.

BCGiosis or tuberculosis was ruled out by biopsy of phalanx. After a few days of treatment, lesions were significantly improved. Treatment with intravenous antibiotics continued for six weeks, and then he was discharged with antibiotic (trimethoprim-sulfamethoxazole) and antifungal prophylaxis (Figure 4).
Figure 4

lesions after treatment.

3. Discussion

Chronic Granulomatous Disease (CGD) is an inherited rare disorder of the immune system and represents with recurrent infections and granuloma formation at different sites [5, 6]. Pneumonia, liver abscess, lymphadenitis, osteomyelitis, and skin (cellulitis or abscesses) are the most important clinical manifestations [4-7]. We have encountered an infant with multiple diffuse vesiculopustular lesions with multiple osteomyelitis but there was no evidence of pneumonia and lymphadenitis. Staphylococcus aureus, gram negative Enterobacteriaceae, and Aspergillus species are the most common pathogens [5, 6]. In our patient, Gram positive cocci were seen in direct smear, and culture was positive for Staphylococcus aureus. We started our treatment with broad spectrum antibiotics and then modified them to vancomycin and amikacin based on culture results. Diagnosis of CGD is based on the DHR test. This test evaluates neutrophil superoxide production via NADPH oxidase complex [4]. Due to diffused and delayed heeling lesions, the NBT and DHR tests were used as diagnostic tests for CGD. As infants with CGD encounter life-threatening infections, early diagnosis and prompt treatment with antibiotics are crucial during acute infections. Antibacterial and antifungal prophylaxes are considered for reducing infections in CGD [5, 6]. Immunotherapy with interferon-γ is sometimes taken and hematopoietic stem cell transplant is also considered in severe forms [8, 9]. In our patient, treatment with intravenous antibiotics continued for 6 weeks and then he was discharged with antibiotic and antifungal prophylaxis. Previous studies presented multifocal abscess [10] and invasive pulmonary aspergillosis [11] as clinical manifestation of CGD during neonatal periods. In our case, multiple diffuse vesiculopustular lesions with multiple osteomyelitis were considered as a clinical presentation of CGD. Despite the rare incidence of CGD during neonatal period, it should be considered in the differential diagnosis of a newborn with clinical features of skin cellulitis or abscesses and multiple osteomyelitis in the absence of appropriate response to treatment with antibiotics.
  7 in total

Review 1.  Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects.

Authors:  Maria Chiriaco; Irene Salfa; Gigliola Di Matteo; Paolo Rossi; Andrea Finocchi
Journal:  Pediatr Allergy Immunol       Date:  2016-01-21       Impact factor: 6.377

2.  Chronic granulomatous disease with unusual clinical manifestation, outcome, and pattern of inheritance in an Iranian family.

Authors:  Saeed F Tafti; Payam Tabarsi; Nahal Mansouri; Mehdi Mirsaeidi; Mohamad A Motazedi Ghajar; Shirin Karimi; Hossain M Najar; Davood Mansouri
Journal:  J Clin Immunol       Date:  2006-05-05       Impact factor: 8.317

3.  A neonatal case of chronic granulomatous disease, initially presented with invasive pulmonary aspergillosis.

Authors:  Sachiko Saito; Arata Oda; Masashi Kasai; Kisei Minami; Haruo Nagumo; Masaaki Shiohara; Yoshifumi Ogiso; Yoshiyuki Kawakami
Journal:  J Infect Chemother       Date:  2013-12-11       Impact factor: 2.211

Review 4.  Chronic Granulomatous Disease.

Authors:  Amit Rawat; Sagar Bhattad; Surjit Singh
Journal:  Indian J Pediatr       Date:  2016-02-11       Impact factor: 1.967

Review 5.  Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression.

Authors:  Josef Ben-Ari; Ofir Wolach; Ronit Gavrieli; Baruch Wolach
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

6.  Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study.

Authors:  Baldassarre Martire; Roberto Rondelli; Annarosa Soresina; Claudio Pignata; Teresa Broccoletti; Andrea Finocchi; Paolo Rossi; Marco Gattorno; Marco Rabusin; Chiara Azzari; Rosa M Dellepiane; Maria C Pietrogrande; Antonino Trizzino; Paolo Di Bartolomeo; Silvana Martino; Luigi Carpino; Fausto Cossu; Franco Locatelli; Rita Maccario; Paolo Pierani; Maria C Putti; Achille Stabile; Luigi D Notarangelo; Alberto G Ugazio; Alessandro Plebani; Domenico De Mattia
Journal:  Clin Immunol       Date:  2007-11-26       Impact factor: 3.969

7.  Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation.

Authors:  Theresa Cole; Mark S Pearce; Andrew J Cant; Catherine M Cale; David Goldblatt; Andrew R Gennery
Journal:  J Allergy Clin Immunol       Date:  2013-07-16       Impact factor: 10.793

  7 in total
  2 in total

1.  Cutaneous and systemic granulomatosis in ataxia-telangiectasia: a clinico-pathological study.

Authors:  Aleksandra Szczawińska-Popłonyk; Katarzyna Olejniczak; Katarzyna Tąpolska-Jóźwiak; Maciej Boruczkowski; Katarzyna Jończyk-Potoczna; Jadwiga Małdyk; Anna Bręborowicz
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

2.  Case Report: Symptomatic Chronic Granulomatous Disease in the Newborn.

Authors:  Milica Miladinovic; Boris Wittekindt; Sebastian Fischer; Elise Gradhand; Steffen Kunzmann; Stefanie Y Zimmermann; Shahrzad Bakhtiar; Thomas Klingebiel; Rolf Schlösser; Thomas Lehrnbecher
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.